Search results for "Assays"

showing 10 items of 546 documents

Synthesis and biological evaluation of sphingosine kinase 2 inhibitors with anti-inflammatory activity.

2019

The synthesis of inhibitors of SphK2 with novel structural scaffolds is reported. These compounds were designed from a molecular modeling study, in which the molecular interactions stabilizing the different complexes were taken into account. Particularly interesting is that 7‐bromo‐2‐(2‐phenylethyl)‐2,3,4,5‐tetrahydro‐1,4‐epoxynaphtho[1,2‐b]azepine, which is a selective inhibitor of SphK2, does not exert any cytotoxic effects and has a potent anti‐inflammatory effect. It was found to inhibit mononuclear cell adhesion to the dysfunctional endothelium with minimal impact on neutrophil–endothelial cell interactions. The information obtained from our theoretical and experimental study can be us…

medicine.drug_classCell SurvivalNeutrophilsFísico-Química Ciencia de los Polímeros ElectroquímicaCellAnti-Inflammatory AgentsPharmaceutical ScienceSYNTHESIS01 natural sciencesPeripheral blood mononuclear cellAnti-inflammatoryANTI-INFLAMMATORY ACTIVITYchemistry.chemical_compoundStructure-Activity RelationshipDrug DiscoverymedicineCell AdhesionHuman Umbilical Vein Endothelial CellsCytotoxic T cellHumansMOLECULAR MODELINGAzepineEnzyme Inhibitors010405 organic chemistryBIOASSAYSCiencias QuímicasSphingosine Kinase 2AdhesionAzepines0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistrySPHK2Phosphotransferases (Alcohol Group Acceptor)medicine.anatomical_structurechemistrySPHINGOSINE KINASE 2 INHIBITORSDrug DesignCancer researchEpoxy CompoundsEndothelium VascularCIENCIAS NATURALES Y EXACTASProtein BindingArchiv der Pharmazie
researchProduct

(+)-Dehydroabietylamine derivatives target triple-negative breast cancer.

2015

Breast cancer remains the leading cause of cancer-related death among women. The invasive triple-negative subtype is unresponsive to estrogen therapy, and few effective treatments are available. In search of new chemical scaffolds to target this disease, we conducted a phenotypic screen against the human breast carcinoma cell lines MDA-MB-231, MA11, and MCF-7 using terrestrial natural products. Natural products that preferentially inhibited proliferation of triple-negative MDA-MB-231 cells over estrogen receptor-positive cells were further studied; herein we focused on the abietanes. The activity of the abietane carnosol prompted us to generate a focus library from the readily available (+)…

medicine.drug_classPhenotypic screeningApoptosisTriple Negative Breast NeoplasmsPharmacologyCarnosolchemistry.chemical_compoundStructure-Activity RelationshipBreast cancerCell Line TumorDrug DiscoverymedicineHumansTriple-negative breast cancerCell ProliferationPharmacologyBiological ProductsDose-Response Relationship DrugMolecular StructureCell growthDrug discoveryOrganic ChemistryStereoisomerismGeneral MedicineTriple Negative Breast Neoplasmsmedicine.diseaseAntineoplastic Agents PhytogenicchemistryEstrogenAbietanesMCF-7 CellsFemaleDrug Screening Assays AntitumorEuropean journal of medicinal chemistry
researchProduct

Design, synthesis, DNA-binding and cytotoxicity evaluation of new potential combilexines

2002

Combilexines, compounds in which a DNA intercalator is linked to a minor groove binding component, interact with the DNA in a sequence specific manner to yield in most cases compounds with anticancer activity. A series of new compounds closely related to netropsin in which the two components were linked by an amide group was synthesised as potential combilexines. As some of these compounds showed cytotoxic activity in vitro, an attempt was made to rationalise their mechanism of action. The DNA binding characteristics of the carboxamides were evaluated by thermal denaturation experiments and by ethidium bromide displacement assay. Their ability to inhibit the topoisomerase I was also determi…

medicine.drug_classStereochemistryAntineoplastic AgentsCarboxamideNucleic Acid DenaturationChemical synthesischemistry.chemical_compoundDrug DiscoveryTumor Cells CulturedmedicineA-DNAPharmacologyBinding SitesbiologyTopoisomeraseOrganic ChemistryDNAGeneral MedicineIntercalating AgentschemistryMechanism of actionBiochemistryNetropsinDrug Designbiology.proteinDrug Screening Assays AntitumorTopoisomerase I Inhibitorsmedicine.symptomEthidium bromideCell DivisionDNAEuropean Journal of Medicinal Chemistry
researchProduct

Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib

2019

Despite the huge success of tyrosine kinase inhibitors as anticancer agents, severe side effects are a major problem. In order to overcome this drawback, the first hypoxia-activatable 2-nitroimidazole-based prodrugs of the clinically approved ALK and c-MET inhibitor crizotinib were developed. The 2-aminopyridine functionality of crizotinib (essential for target kinase binding) was considered as ideal position for prodrug derivatization. Consequently, two different prodrugs were synthesized with the nitroimidazole unit attached to crizotinib either via carbamoylation (A) or alkylation (B) of the 2-aminopyridine moiety. The successful prodrug design could be proven by docking studies and a dr…

medicine.drug_classTyrosine kinase inhibitorAntineoplastic Agents01 natural sciencesBiochemistryArticleTyrosine-kinase inhibitorStructure-Activity Relationshipchemistry.chemical_compoundDrug DevelopmentCrizotinibIn vivoDrug DiscoverymedicineHumansAnaplastic Lymphoma KinaseProdrugsHypoxiaProdrugProtein Kinase InhibitorsMolecular BiologyCells CulturedCell ProliferationNitroimidazoleDose-Response Relationship DrugMolecular StructureCrizotinib010405 organic chemistryChemistryNitroimidazoleOrganic ChemistryProto-Oncogene Proteins c-metProdrugCell Hypoxia0104 chemical sciences010404 medicinal & biomolecular chemistrySettore CHIM/03 - Chimica Generale E InorganicaDocking (molecular)Cancer researchDrug Screening Assays AntitumorKinase bindingTyrosine kinasemedicine.drugBioorganic Chemistry
researchProduct

Prevalence estimation of celiac disease in the general adult population of Latvia using serology and HLA genotyping

2015

Background: Prevalence estimates for celiac disease (CD) depend on the method used. The role of deamidated gliadin peptide (DGP) and genetic testing in epidemiological studies and diagnostic settings of celiac disease (CD) has still to be established. Objectives: The objective of this article is to assess the prevalence of CD in Latvia by combining serological tests with DQ2.5/ DQ8 testing. Methods: A total of 1444 adults from a randomly selected cross-sectional general population sample were tested by ELISA for tTG IgA, DGP IgA and IgG antibodies (QUANTA Lite, Inova Diagnostics Inc). Samples with tTG IgA 20U were tested for EMA IgA by indirect immunofluorescence assay, and all specimens wi…

medicine.medical_specialty:MEDICINE [Research Subject Categories]Tissue transglutaminasePopulationSerologyChemiluminescent assaysEpidemiologyGenotypePrevalenceCeliac diseaseMedicineDQ2.5/8 genotypeeducationGenotypingGenetic testingeducation.field_of_studyDeamidated gliadin peptidemedicine.diagnostic_testbiologybusiness.industryTissue transglutaminaseGastroenterologynutritional and metabolic diseasesOriginal ArticlesOncologyImmunologybiology.proteinAntibodybusinessUnited European Gastroenterology Journal
researchProduct

IFN-alpha Stimulates Proliferation and Cytokine Secretion of CD40-Stimulated B Cell Chronic Lymphocytic Leukemia Cells In Vitro

1999

Interferon (IFN)-alpha has a therapeutic effect in several B cell malignancies, including low-grade non-Hodgkin's lymphoma (NHL), multiple myeloma, and hairy cell leukemia, whereas its efficacy in the treatment of B cell chronic lymphocytic leukemia (B-CLL) is rather limited. In the present study, we investigated the effect of IFN-alpha on the biologic functions of B-CLL cells, which were stimulated by cross-linking of the CD40 antigen. In cell samples from 16 B-CLL patients, the addition of IFN-alpha to CD40-stimulated purified B-CLL cells caused a significant increase in [3H]thymidine uptake (p < 0.003). In B-CLL cells maximally activated by CD40 cross-linking and interleukin-2 (IL-2)/IL-…

medicine.medical_specialtyAdoptive cell transferImmunologyNaive B cellAntineoplastic Agentsimmune system diseaseshemic and lymphatic diseasesVirologyInternal medicineTumor Cells CulturedmedicineHumansHairy cell leukemiaCD40 AntigensCells CulturedB cellCD20B-LymphocytesCD40biologyChemistryInterferon-alphaCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellStimulation ChemicalClone CellsEndocrinologymedicine.anatomical_structurebiology.proteinCancer researchCytokinesCytokine secretionDrug Screening Assays AntitumorCD5Cell DivisionJournal of Interferon &amp; Cytokine Research
researchProduct

Diacylglycerol kinase α mediatses 17-β-estradiol-induced proliferation, motility, and anchorage-independent growth of Hec-1A endometrial cancer cell …

2011

Increased levels of endogenous and/or exogenous estrogens are one of the well known risk factors of endometrial cancer. Diacylglycerol kinases (DGKs) are a family of enzymes which phosphorylate diacylglycerol (DAG) to produce phosphatidic acid (PA), thus turning off and on DAG-mediated and PA-mediated signaling pathways, respectively. DGK α activity is stimulated by growth factors and oncogenes and is required for chemotactic, proliferative, and angiogenic signaling in vitro. Herein, using either specific siRNAs or the pharmacological inhibitor R59949, we demonstrate that DGK α activity is required for 17-β-estradiol (E2)-induced proliferation, motility, and anchorage-independent growth of …

medicine.medical_specialtyGPR30medicine.drug_classCell SurvivalDiacylglycerol kinaseMotilityEstrogen receptorEnzyme AssayEndometrial carcinomaBiologyQuinazolinoneReceptors G-Protein-CoupledPiperidinePiperidinesCell MovementInternal medicineCell Line TumormedicineCell AdhesionHumansEndometrial NeoplasmEnzyme AssaysQuinazolinonesDiacylglycerol kinaseCell ProliferationEstradiolCell growthKinaseCell BiologyDiacylglycerol kinase; Endometrial carcinoma; Estrogen; GPR30; Cell BiologyEstrogenEndometrial NeoplasmsCell biologyEnzyme ActivationLipoprotein LipaseEndocrinologyReceptors EstrogenEstrogenGene Knockdown TechniquesGene Knockdown TechniqueFemaleRNA InterferenceSignal transductionGPERHuman
researchProduct

ShRNA-mediated knock-down of CXCL8 inhibits tumor growth in colorectal liver metastasis.

2018

CXCL8 belongs to proinflammatory chemokines that are predominantly involved in neutrophil chemotaxis and degranulation. Several studies have suggested that secretion of CXCL8 from cancer cells have a profound effect on tumor microenvironment. In this study, in continuation to our previous work of understanding the global picture of invasion related genes in colorectal liver metastases, we clearly show an up-regulation of CXCL8 expression in the tumor cells at the invasion front as compared to the tumor cells in the inner parts of the tumor. Furthermore, ShRNA mediated down-regulation of CXCL8 resulted in inhibition of cell proliferation, viability and invasion in vitro and a near complete g…

musculoskeletal diseases0301 basic medicineAngiogenesisCell SurvivalBiophysicsDown-RegulationApoptosisBiologyBiochemistryProinflammatory cytokineMetastasis03 medical and health sciencesMice0302 clinical medicineCell Line TumormedicineAnimalsHumansNeoplasm InvasivenessAmino Acid SequenceRNA MessengerRNA Small InterferingMolecular BiologyProtein kinase BConserved SequenceCell ProliferationTumor microenvironmentInterleukin-8Liver NeoplasmsCell Biologymedicine.diseaseXenograft Model Antitumor AssaysUp-RegulationGene Expression Regulation NeoplasticVascular endothelial growth factor A030104 developmental biologyTumor progression030220 oncology & carcinogenesisGene Knockdown TechniquesCancer cellCancer researchColorectal NeoplasmsBiochemical and biophysical research communications
researchProduct

Myotonic dystrophy: candidate small molecule therapeutics

2017

Myotonic dystrophy type 1 (DM1) is a rare multisystemic neuromuscular disorder caused by expansion of CTG trinucleotide repeats in the noncoding region of the DMPK gene. Mutant DMPK transcripts are toxic and alter gene expression at several levels. Chiefly, the secondary structure formed by CUGs has a strong propensity to capture and retain proteins, like those of the muscleblind-like (MBNL) family. Sequestered MBNL proteins cannot then fulfill their normal functions. Many therapeutic approaches have been explored to reverse these pathological consequences. Here, we review the myriad of small molecules that have been proposed for DM1, including examples obtained from computational rational …

musculoskeletal diseases0301 basic medicineTherapeutic gene modulationcongenital hereditary and neonatal diseases and abnormalitiesMutantComputational biologyBiologyMyotonic dystrophyMyotonin-Protein Kinase03 medical and health sciences0302 clinical medicineTrinucleotide RepeatsDrug DiscoveryGene expressionmedicineAnimalsHumansMyotonic DystrophyGenePharmacologyRegulation of gene expressionGeneticsDrug RepositioningRational designmedicine.diseaseSmall moleculeHigh-Throughput Screening Assays030104 developmental biologyGene Expression RegulationDrug Design030217 neurology & neurosurgeryDrug Discovery Today
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct